Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data
Abstract Background The recommendation for postoperative chemotherapy in pancreatic ductal adenocarcinoma (PDAC) is based on prospective randomized trials. However, patients included in clinical trials do not often reflect the overall patient population treated in clinical practice. Materials and me...
Main Authors: | Sophia Chikhladze, Ann-Kathrin Lederer, Lampros Kousoulas, Marilena Reinmuth, Olivia Sick, Stefan Fichtner-Feigl, Uwe A. Wittel |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12957-019-1732-3 |
Similar Items
-
An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
by: Zengyu Feng, et al.
Published: (2021-04-01) -
Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy
by: S. A. Safi, et al.
Published: (2021-03-01) -
Metabolism remodeling in pancreatic ductal adenocarcinoma
by: Jin-Tao Li, et al.
Published: (2019-11-01) -
Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment
by: Brad L. Jakubison, et al.
Published: (2018-06-01) -
[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
by: Felix N. Harder, et al.
Published: (2021-07-01)